# A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

> **NCT01922843** · PHASE2 · COMPLETED · sponsor: **Deltanoid Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Hyperparathyroidism, Secondary
- Kidney Failure, Chronic

## Interventions

- **DRUG:** DP001 softgel capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01922843
- **Lead sponsor:** Deltanoid Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922843, "A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01922843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*